MDWD News and Press, MediWound Ltd. From 05/04/20

YAVNE, Israel, May 04, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet medical needs in severe burn and wound management, today announced the expansion of its NexoBrid ® European presen...

YAVNE, Israel, April 27, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced the appointments of Mr. Samuel Moed and Mr. David Fox to it...

Altimmune (NASDAQ: ALT ) will collaborate with the University of Alabama at Birmingham on the development of a single-dose intranasal COVID-19 vaccine called AdCOVID. Shares up  7%  premarket. More news on: Altimmune, Inc., Vir Biotechnology, Inc., MediWound Ltd., Healthcare st...

YAVNE, Israel, March 30, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (the “Company”), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today provided an update on certain impacts o...

YAVNE, Israel, Feb. 28, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that Sharon Malka, MediWound’s Chief Executive Office...

Today, we will study why Organogenesis ( ORGO ) is a high growth yet undervalued opportunity in 2020. Company overview Organogenesis is a regenerative medicine company focusing on the development and commercialization of products for treating chronic and acute wounds and healing of muscu...

Mediwound Ltd (MDWD) Q4 2019 Earnings Conference Call February 25, 2020, 08:30 ET Company Participants Jeremy Feffer - LifeSci Advisors Sharon Malka - CEO Boaz Gur-Lavie - CFO Conference Call Participants Joshua Jennings - Cowen and Company Swayampakula Ramakanth - H.C. ...

MediWound (NASDAQ: MDWD ): Q4 GAAP EPS of -$0.13 misses by $0.03 . More news on: MediWound Ltd., Earnings news and commentary, Healthcare stocks news, , Read more ...

Generated total full-year 2019 revenues of $31.8 million, driven primarily by Vericel license payment and development services to BARDA Initiated U.S. Phase 2 adaptive design study of EscharEx for the treatment of venous leg ulcers BARDA initiated the procurement of NexoBrid value...

YAVNE, Israel, Feb. 18, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that the Company will release its financial results for the ...